Hematologic Malignancies
Autolus Limited focuses on B-cell acute lymphoblastic leukemia and aggressive mature B-cell non-Hodgkin lymphoma, with research centered on CD19-directed CAR T-cell therapy for relapsed or refractory disease in both adult and pediatric populations.
- Relapsed or refractory B-cell acute lymphoblastic leukemia
- Aggressive mature B-cell non-Hodgkin lymphoma
- Pediatric B-cell malignancies
Its oncology portfolio also includes follow-up studies in patients previously treated with genetically modified autologous T cells.
Autoimmune Kidney Disease
The sponsor is active in systemic lupus erythematosus with active lupus nephritis and in severe refractory lupus, reflecting interest in immune-mediated renal disease and difficult-to-treat autoimmune inflammation.
- Severe refractory systemic lupus erythematosus
- Systemic lupus erythematosus with active lupus nephritis
- Complete renal response
Research in this area examines cell therapy approaches for patients with persistent kidney involvement.
Neurology and Demyelinating Disease
Autolus Limited also funds work in refractory progressive multiple sclerosis, extending its therapeutic interest into chronic inflammatory disorders of the central nervous system.
- Progressive multiple sclerosis
- Refractory disease
- Immune-mediated neurologic disorders
This area reflects attention to neuroinflammation and treatment-resistant disease activity.
Long-Term Safety and Cellular Therapy Follow-Up
The sponsor supports ongoing evaluation of long-term safety and persistent clinical effects after CAR T-cell therapy and other autologous T-cell products.
- Long-term follow-up
- Cell therapy safety
- Post-treatment monitoring
These studies include continued observation of patients previously exposed to viral vector-modified T cells.
